Agonists of the TRAIL death receptor DR5 sensitize intestinal stem cells to chemotherapy-induced cell death and trigger gastrointestinal toxicity

The combination of TRAIL death receptor agonists and radiochemotherapy to treat advanced cancers continues to be investigated in clinical trials. We previously showed that normal cells with a functional DNA damage response (DDR) upregulate the expression of death inducing receptor DR5/TRAILR2/TNFRSF...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Res
Main Authors: Finnberg, Niklas K., Gokare, Prashanth, Navaraj, Arunasalam, Lang Kuhs, Krystle A., Cerniglia, George, Yagita, Hideo, Takeda, Kazuyoshi, Motoyama, Noboru, El-Deiry, Wafik S.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5001853/
https://ncbi.nlm.nih.gov/pubmed/26609054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-2759
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items